Epix touts data on pulmonary hypertension drug
Shares of Epix Pharmaceuticals were buoyed this morning by positive data from a mid-stage study of a drug designed to reduce high blood pressure in the pulmonary artery. The trial of PRX-08066 involved 71 patients with pulmonary hypertension associated with COPD. Lexington, MA-based Epix also reported that its losses ballooned in the second quarter due to swelling R&D costs.
- see the release for more
Related Articles:
Epix shares soar on $1.2B pact with GSK. Report
Epix anxiety drug fails in late-stage trial. Report
Epix to buy Predix in $90M merger. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
